All Comments by Stefan Lichtenthaler
- Scratch Lanabecestat: This BACE Inhibitor Doesn’t Work in Symptomatic AD, Either
- BACE1 Conditional Knockouts Model Adult BACE Inhibition
- Merck Axes Verubecestat for Prodromal AD, Researchers Say ‘Go Earlier’
- More Support for Amyloid Hypothesis: Protective APP Mutation Lowers Aβ in Blood
- Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- New MO for Purported Anti-Amyloid Drug: Shielding APP from BACE?
- Paper Alert: Verubecestat Preclinical and Phase 1 Data Published
- Partners in Crime: APP Fragment and Endosomal Protein Impair Endocytosis
- Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice.
- β-Secretase BACE1 regulates hippocampal and reconstituted M-currents in a β-subunit-like fashion.
- Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions.
- Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes.
- Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle spindles.
- Lilly Halts Phase 2 Trial of BACE Inhibitor Due to Liver Toxicity
- β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment.